Shingles vaccine gives GSK boost
GlaxoSmithKline has upgraded its full-year guidance following strong sales of its shingles vaccine.
The group said revenue garnered from Shingrix now expected to be between £700m and £750m in 2018, helping it pencil in earnings per share growth of between 8 and 10 per cent.
Previously, GSK expected Shingrix sales at between £600m and £650m. It came as GSK booked pre-tax profit of £1.71bn in the three months to September, broadly unchanged from the year before. Revenue grew to £8.09bn from